Retatrutide: The Triple Agonist the GLP-1 Forums Have Been Waiting For

Every year or two the GLP-1 world gets a new top dog. Liraglutide handed the belt to semaglutide. Semaglutide handed it to tirzepatide. And then in 2023 Eli Lilly dropped the retatrutide Phase 2 data — 24% mean weight loss at 48 weeks at the top dose — and every metabolic forum on the internet lost its mind.

The drug isn't approved. Phase 3 is still running. But in the community, "Reta" is already a first name.

What it is, in one paragraph

Retatrutide is a 39-amino-acid peptide that hits three receptors at once: GLP-1 (appetite, insulin, delayed gastric emptying), GIP (insulin, adipose tissue biology), and glucagon (energy expenditure, hepatic fat oxidation). That last one — the glucagon receptor — is the new trick. Glucagon normally raises blood sugar, which sounds like the wrong direction for a diabetes drug, but GLP-1 and GIP agonism offset the glycemic side while letting glucagon turn up energy burn and strip hepatic fat. It's once-weekly, albumin-bound via a C20 fatty diacid chain. Think tirzepatide with an energy-expenditure upgrade.

Dosing: what people actually do

The community follows Eli Lilly's Phase 2 titration closely because (a) it's the only clinical map that exists and (b) not titrating on this class is how you end up vomiting for a week.

• Week 1–4: 2 mg once weekly
• Week 5–8: 4 mg once weekly
• Week 9–12: 6 mg once weekly
• Week 13+: 8 mg weekly (standard) or 12 mg weekly (aggressive, often split into two 6 mg shots)

Most forum users settle between 4 and 8 mg for a long cruise. Twelve is possible, but the GI cost gets real. Same-day-every-week, sub-Q in the usual spots (abdomen, thigh, upper arm), site rotation matters more than people realize.

"At 8 mg for a month my appetite basically unhooked itself, but what surprised me was body temp — I was genuinely warmer. My watch had my resting HR up like 4 bpm. That's the glucagon piece, I think." — forum user

What it pairs with

• Resistance training + high protein — not optional. Any GLP-1 class drug pulls ~25–35% of weight loss from lean mass unless you actively defend it
• Creatine, taurine, electrolytes — GI changes, appetite drops, hydration needs attention
• 5-Amino-1MQ for people going hard on body composition
• BPC-157 if GI symptoms are rough early in titration (anecdotal; the gut-healing angle is what people reach for)
• Not usually stacked with semaglutide or tirzepatide. Pick one incretin, not three

Red flags and side effects

The GLP-1 class side effects apply, plus glucagon-specific things to watch:

• GI: nausea, vomiting, diarrhea — same as tirzepatide/semaglutide, worse if you titrate too fast
• Heart rate: glucagon raises it. Small bumps are expected; sustained elevation is a red flag
• Lean mass loss: real, prevented by training + protein
• Hepatic response: liver fat drops dramatically (that's the point), but people with existing hepatic issues should be paying attention
• Sulfur burps, fatigue, constipation — the usual GLP-1 quirks
• Not approved. Supply quality is all over the place. COA or don't

The honest limits

• Phase 2 is 48 weeks. We don't have long-term data. Weight regain off-drug is already a known issue with this class, and there's no reason to think Reta is different
• The glucagon piece adds safety questions that tirzepatide doesn't have. Bone density, lean mass, cardiac output — Phase 3 (TRIUMPH) is specifically watching these
• It's not approved anywhere as of 2026. Every user is working with research-grade supply. Quality ranges wildly
• "Better than tirz by a couple percent" is the actual Phase 2 margin at comparable timepoints — impressive, but not night-and-day

Where to go next

• For the full Phase 2 data, receptor mechanism, and triple-agonist theory, see the Pepperpedia Retatrutide entry.
• For live user logs, dose-split strategies, and GI-management threads, the Optimization forum is where the action is.
• Titration math from a 10 mg vial? PepperCalc does the unit conversions.
• Cross-shopping against the rest of the class? See Tirzepatide and Semaglutide.